- Home
- OKUR
as 11-21-2024 4:00pm EST
Stocks
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 234.2M | IPO Year: | N/A |
| Target Price: | $37.50 | AVG Volume (30 days): | 58.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.80 - $77.60 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ONKURE THERAPEUTICS INC News
OKUR Breaking Stock News: Dive into OKUR Ticker-Specific Updates for Smart Investing
GlobeNewswire
16 days ago
OnKure to Present at the Stifel 2024 Healthcare Conference
GlobeNewswire
20 days ago
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium
Compare OKUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OKUR ONKURE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.